TY - JOUR
T1 - Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction
T2 - Insights from the echocardiographic substudy of the VICTORIA trial
AU - VICTORIA Study Group
AU - Tromp, Jasper
AU - Lam, Carolyn S.P.
AU - Alemayehu, Wendimagegn
AU - de Filippi, Christopher R.
AU - Melenovský, Vojtěch
AU - Sliwa, Karen
AU - Lopatin, Yuri
AU - Arango, Juan Luis
AU - Bahit, M. Cecilia
AU - Roessig, Lothar
AU - O'Connor, Christopher M.
AU - Shah, Palak
AU - Westerhout, Cynthia M.
AU - Voors, Adriaan A.
AU - Pieske, Burkert
AU - Armstrong, Paul W.
N1 - Publisher Copyright:
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2024/10
Y1 - 2024/10
N2 - Aims: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear. Methods and results: We evaluated paired core-lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57–74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow-up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77–0.88), growth differentiation factor-15 (ratio 0.74, 95% CI 0.66–0.84), and insulin-like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73–0.88). Conclusions: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism.
AB - Aims: Reverse ventricular remodelling, defined as a decrease in left ventricular end-systolic volume indexed to body surface area (LVESVI) or an increase in left ventricular ejection fraction (LVEF), is associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, the underlying pathophysiological mechanisms remain unclear. Methods and results: We evaluated paired core-lab assessed echocardiograms and measurements of 92 biomarkers at baseline and 8 months thereafter in 419 participants with HFrEF. Reverse ventricular remodelling was defined as a >5% LVEF increase or >15% LVESVI relative decrease between baseline and 8 months. We evaluated the association between baseline biomarkers and their changes with reverse ventricular remodelling in the prospectively randomized controlled VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial. Of 419 patients (median age 66 [interquartile range 57–74] years, 27.4% women), 206 (49.2%) had reverse ventricular remodelling (either a 5% LVEF increase or a 15% LVESVI decrease). There were no differences in baseline biomarker concentrations between patients with versus those without reverse ventricular remodelling on follow-up. However, in patients with reverse ventricular remodelling there were significant decreases in biomarkers relating to inflammation and cardiac metabolism; particularly the tumour necrosis factor superfamily member 13B (ratio 0.82, 95% confidence interval [CI] 0.77–0.88), growth differentiation factor-15 (ratio 0.74, 95% CI 0.66–0.84), and insulin-like growth factor binding protein 7 (ratio 0.80, 95% CI 0.73–0.88). Conclusions: Reverse ventricular remodelling in patients with HFrEF is associated with a decrease of biomarkers related to inflammation and cardiac metabolism.
KW - Biomarkers
KW - Cardiac remodelling
KW - Heart failure with reduced ejection fraction
UR - https://www.scopus.com/pages/publications/85200036044
U2 - 10.1002/ejhf.3397
DO - 10.1002/ejhf.3397
M3 - Article
AN - SCOPUS:85200036044
SN - 1388-9842
VL - 26
SP - 2231
EP - 2239
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 10
ER -